<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701463</url>
  </required_header>
  <id_info>
    <org_study_id>0912/14122018</org_study_id>
    <nct_id>NCT04701463</nct_id>
  </id_info>
  <brief_title>A Specialized Amino Acid Mixture on Body Composition and Skin State in Overweight and Obese Class I Postmenopausal Women</brief_title>
  <official_title>Effect of a Specialized Amino Acid Mixture on Body Composition and Skin State in Overweight and Obese Class I Sedentary Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda di Servizi alla Persona di Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda di Servizi alla Persona di Pavia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of dietary amino acids has been explored for therapeutic and safety intervention of&#xD;
      obesity and obesity-induced dysfunction. In particular, 3 molecules have been shown to be&#xD;
      effective both in the animal model and in humans, in promoting the loss of fat mass,&#xD;
      specifically visceral adipose tissue, and in maintaining free fat mass: arginine, glutamine&#xD;
      and leucine (and its metabolite beta hydroxy methyl butyrate, HMB). The aim of this study was&#xD;
      to evaluate the efficacy in terms of fat mass, in particular Visceral Adipose Tissue&#xD;
      reduction, as primary end point, in obese patients following the administration of specific&#xD;
      food for special medical purposes (FSMP) for muscle recovery, consisting of arginine,&#xD;
      glutamine and HMB. The secondary end point is the evaluation of skin state, by a validate&#xD;
      self-reported questionnaire survey to assess skin, after 4- weeks intake of this FSMP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Actual">November 25, 2020</completion_date>
  <primary_completion_date type="Actual">November 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes on Visceral Adipose Tissue</measure>
    <time_frame>Baseline / 30 days</time_frame>
    <description>Evaluation of Visceral Adipose Tissue (g)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes on Body Composition</measure>
    <time_frame>Baseline / 30 days</time_frame>
    <description>Evaluation of fat mass and fat free mass (g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on Metabolic parameters</measure>
    <time_frame>Baseline / 30 days</time_frame>
    <description>Evaluation of Fasting blood glucose (mg/dl), total cholesterol (mg/dl), low-density lipoprotein-cholesterol (mg/dl), high-density lipoprotein-cholesterol (mg/dl) and triglyceride levels (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on Metabolic parameters</measure>
    <time_frame>Baseline / 30 days</time_frame>
    <description>Evaluation of insulin (mcIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on Metabolic parameters</measure>
    <time_frame>Baseline / 30 days</time_frame>
    <description>Evaluation of insulin resistance (HOMA index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometric measurements</measure>
    <time_frame>Baseline / 30 days</time_frame>
    <description>Evaluation of body weight (kg) and height (m) combined for Body Mass Index (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometric measurements</measure>
    <time_frame>Baseline / 30 days</time_frame>
    <description>Evaluation of waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on skin condition</measure>
    <time_frame>Baseline / 30 days</time_frame>
    <description>Administration of a questionnaire survey with a point evaluation scale from 0 to 5 (Oe et al, 2017). For the skin luster and suppleness, one is the worst and five is the best. For the wrinkles, one is least wrinkles; not worry, and five is most wrinkles; most care.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Amino Acid</condition>
  <condition>Body Weight Changes</condition>
  <condition>Skin Manifestations</condition>
  <condition>Obesity</condition>
  <condition>Postmenopausal Disorder</condition>
  <arm_group>
    <arm_group_label>L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate</intervention_name>
    <description>2 daily sachets (mid morning and mid afternoon) of an oral dietary supplement with L-glutamine and L-arginine and calcium beta-hydroxy-beta-methylbutyrate</description>
    <arm_group_label>L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Isocaloric formula</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopause&#xD;
&#xD;
          -  Obesity (I class) or overweight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking any medication&#xD;
&#xD;
          -  Having liver, renal and thyroid disease&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Drinking more than two standard alcoholic beverages/day (20 g of alcohol/day)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda di Servizi alla Persona</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Body Weight Changes</mesh_term>
    <mesh_term>Skin Manifestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

